drugset / Trial / NCT00038974

Summary

This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied.

Timeline

Start
2002-08
Primary completion
2004-12
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon alfa-2a Protein / enzyme biologic 180 ug
Subject Ribavirin Small molecule 1000 mg
Subject Ribavirin Small molecule 1200 mg